Furiex Pharmaceuticals Inc  

(Public, NASDAQ:FURX)   Watch this stock  
Find more results for FURX
104.77
Jul 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 32.05 - 121.97
Open     -
Vol / Avg. 0.00/220,427.00
Mkt cap 1.13B
P/E     -
Div/yield     -
EPS -5.05
Shares 10.82M
Beta 1.82
Inst. own 68%
Aug 4, 2014
Q2 2014 Furiex Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -203.22% -41.79%
Operating margin -177.81% -34.42%
EBITD margin - -34.34%
Return on average assets -62.11% -32.39%
Return on average equity -359.25% -105.90%
Employees 24 -
CDP Score - -

Address

3900 Paramount Pkwy Ste 150
MORRISVILLE, NC 27560-5401
United States - Map
+1-919-4567800 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company´┐Żs product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.